Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.39 |
| ▸ | CNR1 | P21554 | 6/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1497856 | 0.85 | LMNA (0.36) | CNR2CNR1ALDH1A1 | |
| SCHEMBL1497793 | 0.82 | GAA (0.38) | CNR2CNR1GAARAD52KDM4E | |
| SCHEMBL1497887 | 0.75 | HTR3A (0.60) | CNR2CNR1 | |
| SCHEMBL6481040 | 0.74 | MEN1 (0.56) | GAAMEN1KMT2A | |
| SCHEMBL1497720 | 0.74 | PDE10A (0.39) | CNR2CNR1GAARAD52KDM4E | |
| SCHEMBL1497874 | 0.73 | ALDH1A1 (0.40) | CNR2CNR1GAARAD52KDM4E | |
| SCHEMBL1497869 | 0.73 | CYP3A4 (0.57) | CNR2CNR1 | |
| SCHEMBL23937800 | 0.71 | NR4A2 (0.40) | GAAKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL20674231 | 0.71 | LMNA (0.43) | CNR1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL1497909 | 0.70 | CYP3A4 (0.53) | CNR2CNR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897614-B2 | Preventive agent/remedial agent for constipation predominant IBS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20100210679-A1 | PREVENTIVE AND THERAPEUTIC MEDICAMENT FOR GASTROESOPHAGEAL REFLUX DISEASE | YAMAZAKI SATOSHI | 2010-08-19 | — | — | US | disclosed |
| US-20100204267-A1 | Preventive and therapeutic medicament for gastroesophageal reflux disease | YAMAZAKI SATOSHI | 2010-08-12 | — | — | US | disclosed |
| US-20100168157-A1 | PREVENTIVE AND THERAPEUTIC MEDICAMENT FOR GASTROESOPHAGEAL REFLUX DISEASE | YAMAZAKI SATOSHI | 2010-07-01 | — | — | US | disclosed |
| EP-1829543-B1 | Preventive agent/remedial agent for constipation predominant IBS | MITSUBISHI TANABE PHARMA CORP (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20080293762-A1 | Preventive and Therapeutic medicament for gastroesophageal reflux disease | EDUSA PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| EP-1829543-A1 | Preventive agent/remedial agent for constipation predominant IBS | MITSUBISHI PHARMA CORPORATION (JP) | 2007-09-05 | — | — | EP | disclosed |
| EP-1419772-B1 | PREVENTIVE AGENT/REMEDIAL AGENT FOR CONSTIPATION PREDOMINANT IBS | MITSUBISHI PHARMA CORP (JP) | 2007-07-25 | — | — | EP | disclosed |
| EP-1256581-B1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR GASTRIC OR ESOPHAGEAL REGURGITATION | MITSUBISHI PHARMA CORP (JP) | 2007-03-28 | — | — | EP | disclosed |
| US-20070004770-A1 | Preventive agent/remedial agent for constipation predominant IBS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-04 | — | — | US | disclosed |
| US-20060281781-A1 | Preventive and therapeutic medicament for gastroesophageal reflux disease | EDUSA PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | disclosed |
| US-20050282852-A1 | Preventive and therapeutic medicament for gastroesophageal reflux disease | YAMAZAKI SATOSHI | 2005-12-22 | — | — | US | disclosed |
| US-6967207-B2 | Preventive or therapeutic agents for gastric or esophageal regurgitation | MITSUBISHI PHARMA CORPORATION (JP) | 2005-11-22 | — | — | US | disclosed |
| US-20040248927-A1 | Preventive agent/remedial agent for constipation predominant ibs | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1419772-A1 | PREVENTIVE AGENT/REMEDIAL AGENT FOR CONSTIPATION PREDOMINANT IBS | Mitsubishi Pharma Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-20030130304-A1 | Preventive or therapeutic agents for gastric or esophageal regurgitation | MITSUBISHI PHARMA CORPORATION (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-1256581-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR GASTRIC OR ESOPHAGEAL REGURGITATION | Mitsubishi Pharma Corporation (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168157-A1 | PREVENTIVE AND THERAPEUTIC MEDICAMENT FOR GASTROESOPHAGEAL REFLUX DISEASE | HRH2, SLC10A2, GRPR | CNR2 382/4885CNR1 402/4885GAA 374/4885 |
| US-20040248927-A1 | Preventive agent/remedial agent for constipation predominant ibs | BRS3, SLC10A2, FABP2 | CNR2 59/4885CNR1 122/4885GAA 4082/4885 |
| US-20070004770-A1 | Preventive agent/remedial agent for constipation predominant IBS | SLC10A2, FABP2, SI | CNR2 31/4885CNR1 42/4885GAA 3525/4885 |
| US-20050282852-A1 | Preventive and therapeutic medicament for gastroesophageal reflux disease | HRH2, SLC10A2, GRPR | CNR2 382/4885CNR1 402/4885GAA 374/4885 |
| US-20100210679-A1 | PREVENTIVE AND THERAPEUTIC MEDICAMENT FOR GASTROESOPHAGEAL REFLUX DISEASE | HRH2, SLC10A2, GRPR | CNR2 382/4885CNR1 402/4885GAA 374/4885 |
| US-20100204267-A1 | Preventive and therapeutic medicament for gastroesophageal reflux disease | HRH2, SLC10A2, GRPR | CNR2 382/4885CNR1 402/4885GAA 374/4885 |
| US-20080293762-A1 | Preventive and Therapeutic medicament for gastroesophageal reflux disease | HRH2, SLC10A2, GRPR | CNR2 382/4885CNR1 402/4885GAA 374/4885 |
| US-20060281781-A1 | Preventive and therapeutic medicament for gastroesophageal reflux disease | HRH2, SLC10A2, GRPR | CNR2 382/4885CNR1 402/4885GAA 374/4885 |
| US-20030130304-A1 | Preventive or therapeutic agents for gastric or esophageal regurgitation | HRH2, SLC10A2, ABCB11 | CNR2 553/4885CNR1 607/4885GAA 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.